可诱导共刺激分子及其在肿瘤中的作用

doi:10.3760/cma.j.issn.1673-422X.2015.07.010

摘要/Abstract

摘要： 可诱导共刺激分子（ICOS）是CD28家族成员之一，可表达于肿瘤组织以及肿瘤微环境中的免疫细胞等。ICOS参与CD4+和CD8+T细胞免疫应答，促进活化的T细胞和NK细胞分泌细胞因子，从而提高抗肿瘤活性。同时细胞毒T淋巴细胞相关抗原4(CTLA4)单克隆抗体治疗疗效与CD4+T细胞表达ICOS有关，因此ICOS可能会成为抗肿瘤的新型治疗靶点。

关键词: 免疫, 肿瘤微环境, 可诱导共刺激分子

Abstract: Inducible costimulatory molecule (ICOS) is a member of the CD28 family, which can be expressed on the tumor tissues and immune cells in the tumor microenvironment. ICOS enhances its antitumor activity through participating in CD4+ T and CD8+ T cell immune response and enhancing the secretion of cytokines on the activated T cells and NK cells. While the curative effect of cytotoxic T lymphocyteassociated antigen4 (CTLA4) monoclonal antibody is relevant with CD4+ T cells expressing ICOS, which suggesting ICOS may become a novel antitumor therapeutic target in the future.

Key words: Immunity, Tumor microenvironment, Inducible costimulatory molecule

吴栋娟，华东. 可诱导共刺激分子及其在肿瘤中的作用[J]. 国际肿瘤学杂志, 2015, 42(7): 516-518.

Wu Dongjuan, Hua Dong. Inducible costimulatory molecule and its roles in tumor microenvironment[J]. Journal of International Oncology, 2015, 42(7): 516-518.

参考文献

［1］ Jemal A, Bray F, Center MM, et al. Global cancer statistics［J］. CA Cancer J Clin, 2011, 61(2): 69-90. ［2］ PolyakK, Haviv I, Campbell IG. Coevolution of tumor cells and their microenvironment［J］. Trends Genet, 2009, 25(1): 30-38. ［3］ Oluwadara O, Giacomelli L, Brant X, et al. The role of the microenvironment in tumor immune surveillance［J］. Bioinformation, 2011, 5(7): 285-290. ［4］ Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T cell costimulator: a structurally and functionally related to CD28［J］. Nature, 1999, 397(6716): 263-266. ［5］ Yao S, Zhu Y, Zhu G, et al. B7h2 is a costimulatory ligand for CD28 in human［J］. Immunity, 2011, 34(5): 729-740. ［6］ Larimore K, Liang L, Bakkour S, et al. B7hexpressing dendritic cells and plasma B cells mediate distinct outcomes of ICOS costimulation in T celldependent antibody responses［J］. BMC Immunol, 2012, 13: 29. ［7］ MartinOrozco N, Li Y, Wang Y, et al. Melanoma cells express ICOS ligand to promote the activation and expansion of Tregulatory cells［J］. Cancer Res, 2010, 70(23): 9581-9590. ［8］ Schreiner B, Wischhusen J, Mitsdoerffer M, et al. Expression of the B7related molecule ICOSL by human glioma cells in vitro and in vivo［J］. Glia, 2003, 44(3): 296-301. ［9］ Rudulier CD, McKinstry KK, AIYassin GA, et al. The number of responding CD4 T cells and the dose of antigen conjointly determine the TH1/TH2 phenotype by modulating B7/CD28 interactions［J］. J Immunol, 2014, 192(11): 5140-5150. ［10］ Chen XL, Cao CD, Kang AJ, et al. In situ expression and significance of B7 costimulatory molecules within tissues of human gastric carcinoma［J］. World J Gastroenterol, 2003, 9(6): 1370-1373. ［11］ Baseggio L, TraverseGlehen A, Berger F, et al. CD10 and ICOS expression by multiparametric flow cytometry in angioimmunoblastic Tcell lymphoma［J］. Modern Pathology, 2011, 24(7): 993-1003. ［12］ Greaves P, Gribben JG. The role of B7 family molecules in hematologic malignancy［J］. Blood, 2013, 121(5): 734-744. ［13］ Zhang Q, Wang H, Kantekure K, et al. Oncogenic tyrosine kinase NPMALK induces expression of the growthpromoting receptor ICOS［J］. Blood, 2011, 118(11): 3062-3071. ［14］ Chen H, Fu T, Suh WK, et al. CD4 T cells require ICOSmediated PI3K signaling to increase TBet expression in the setting of antiCTLA4 therapy［J］. Cancer Immunol Res, 2014, 2(2): 167-176. ［15］ Feyler S, Scott GB, Parrish C, et al. Tumour cell generation of inducible regulatory Tcells in multiple myeloma is contactdependent and antigenpresenting cellindependent［J］. PLoS One, 2012, 7(5): e35981. ［16］ He M, Wang Y, Shi WJ, et al. Immunomodulation of inducible costimulator (ICOS) in human cytokineinduced killer cells against cholangiocarcinoma through ICOS/ICOS ligand interaction［J］. J Dig Dis, 2011, 12(5): 393-400. ［17］ Galicia G, Kasran A, Uyttenhove C, et al. ICOS deficiency results in exacerbated IL17 mediated experimental autoimmune encephalomyelitis［J］. J Clin Immunol, 2009, 29(4): 426-433. ［18］ Chen H, Liakou CI, Kamat A, et al. AntiCTLA4 therapy results in higher CD4+ICOShi T cell frequency and IFNgamma levels in both nonmalignant and malignant prostate tissues［J］. Proc Natl Acad Sci USA, 2009, 106(8): 2729-2734. ［19］ Bogunovic D, O′Neill DW, BelitskayaLevy I, et al. Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival［J］. Proc Natl Acad Sci USA, 2009, 106(48): 20429-20434. ［20］ Gousias K, von Ruecker A, Voulgari P, et al. Phenotypical analysis, relation to malignancy and prognostic relevance of ICOS+T regulatory and dendritic cells in patients with gliomas［J］. J Neuroimmunol, 2013, 264(1-2): 84-90. ［21］ Harshman LC, Drake CG, Wargo JA, et al. Cancer immunotherapy highlights from the 2014 ASCO meeting［J］. Cancer Immunol Res, 2014, 2(8): 714-719. ［22］ Fan X, Quezada SA, Sepulveda MA, et al. Engagement of the ICOS pathway markedly enhances efficacy of CTLA4 blockade in cancer immunotherapy［J］. J Exp Med, 2014, 211(4): 715-725. ［23］ Fu T, He Q, Sharma P. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by antiCTLA4 therapy［J］. Cancer Res, 2011, 71(16): 5445-5454.

[1]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[2]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[3]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[4]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[5]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[6]	傅旖, 马辰莺, 张露, 周菊英. 生境分析在恶性肿瘤影像组学中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 292-297.
[7]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[8]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[9]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[10]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[11]	钟楠, 王淡瑜, 周欢欢, 刘宁, 戴纬, 刘黎琼, 郭智. CD30单抗联合PD-1抑制剂治疗复发难治性霍奇金淋巴瘤的疗效与安全性[J]. 国际肿瘤学杂志, 2024, 51(4): 245-248.
[12]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[13]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[14]	钱晓涛, 石子宜, 胡格. Ⅲ~ⅣA期食管鳞状细胞癌根治性放化疗后行免疫检查点抑制剂维持治疗的真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(3): 151-156.
[15]	解淑萍, 孙亚红, 汪超. 早期肿瘤标志物联合NLR、PLR预测胃癌免疫治疗疗效[J]. 国际肿瘤学杂志, 2024, 51(3): 157-165.